迪迪明通过促进Notch1降解来改善性结肠炎相关的二次肝损伤
Qi Lv1, Juan Wang1, Hongqiong Yang1
1Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
迪迪明是一种类黄胺,通过抑制Notch1信号通路,防止与性结肠炎 (UC) 相关的炎症性肝损伤. 这种机制涉及促进巨细胞中Notch1的溶酶体降解,为结肠炎提供了潜在的治疗策略.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 迪迪明是一种饮食类黄类化合物,具有已知的抗性结肠炎 (UC) 特性.
- 迪迪明在UC相关的炎症性肝损伤中的作用仍然未被探索.
研究的目的:
- 调查迪迪明在UC相关炎症性肝损伤中的治疗潜力.
- 为了阐明底层分子机制的迪迪明的作用.
主要方法:
- 建立了一个DSS诱导的大肠炎小鼠模型,并给予didymin.
- 评估肝损伤标志物 (ALT,AST,组织病理学) 和炎症性细胞因子表达 (Tnf,Il1,Il6).
- 在体外使用Kupffer和RAW264.7细胞来研究didymin对Notch1信号通路的影响.
主要成果:
- 在大肠炎模型中,滴滴胺显著降低了肝损伤标志物和组织病理损伤.
- 迪迪明抑制了肝脏组织和细胞中的促炎性细胞因子mRNA表达.
- 迪迪明抑制了Notch1细胞内域1 (Notch1-ICD) 和Hes1的表达,这取决于c-Cbl介导的溶酶体降解.
结论:
- 迪迪明有效地预防了UC相关的炎症性肝损伤.
- 该机制涉及促进c-Cbl表达和随后的Notch1-ICD在巨细胞中的溶酶体降解.
- 迪迪明代表了大肠炎的潜在治疗剂,对黄类药物研究有影响.
更多相关视频
08:56Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
相关概念视频
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
